

# Rasmi Thomas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3408723/publications.pdf>

Version: 2024-02-01

48  
papers

2,350  
citations

257450

24  
h-index

214800

47  
g-index

53  
all docs

53  
docs citations

53  
times ranked

3887  
citing authors

#	ARTICLE	IF	CITATIONS
1	Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand. <i>Human Immunology</i> , 2022, 83, 53-60.	2.4	3
2	HLA-B*46 associates with rapid HIV disease progression in Asian cohorts and prominent differences in NK cell phenotype. <i>Cell Host and Microbe</i> , 2022, 30, 1173-1185.e8.	11.0	5
3	Genetic variation that determines TAPBP expression levels associates with the course of malaria in an HLA allotype-dependent manner. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	3
4	B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies. <i>Cell Host and Microbe</i> , 2021, 29, 564-578.e9.	11.0	18
5	High-resolution HLA allele and haplotype frequencies in several unrelated populations determined by next generation sequencing: 17th International HLA and Immunogenetics Workshop joint report. <i>Human Immunology</i> , 2021, 82, 505-522.	2.4	17
6	Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1. <i>ELife</i> , 2021, 10, .	6.0	12
7	Dendritic cells focus CTL responses toward highly conserved and topologically important HIV-1 epitopes. <i>EBioMedicine</i> , 2021, 63, 103175.	6.1	10
8	Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. <i>Nature Medicine</i> , 2020, 26, 498-501.	30.7	43
9	Next-generation sequencing of 11 HLA loci in a large dengue vaccine cohort from the Philippines. <i>Human Immunology</i> , 2020, 81, 437-444.	2.4	2
10	Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. <i>Nature Medicine</i> , 2020, 26, 228-235.	30.7	61
11	A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	26
12	Effect of Fc Receptor Genetic Diversity on HIV-1 Disease Pathogenesis. <i>Frontiers in Immunology</i> , 2019, 10, 970.	4.8	10
13	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2019, 6, e297-e306.	4.7	73
14	Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. <i>Nature Communications</i> , 2019, 10, 863.	12.8	27
15	Quality control project of NGS HLA genotyping for the 17th International HLA and Immunogenetics Workshop. <i>Human Immunology</i> , 2019, 80, 228-236.	2.4	27
16	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. <i>Journal of Virology</i> , 2018, 92, .	3.4	45
17	Full-length next-generation sequencing of HLA class I and II genes in a cohort from Thailand. <i>Human Immunology</i> , 2018, 79, 773-780.	2.4	20
18	HLA-C downregulation by HIV-1 adapts to host HLA genotype. <i>PLoS Pathogens</i> , 2018, 14, e1007257.	4.7	30

#	ARTICLE	IF	CITATIONS
19	High-Throughput Contiguous Full-Length Next-Generation Sequencing of HLA Class I and II Genes from 96 Donors in a Single MiSeq Run. <i>Methods in Molecular Biology</i> , 2018, 1802, 89-100.	0.9	9
20	Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. <i>Journal of Clinical Investigation</i> , 2018, 128, 1903-1912.	8.2	52
21	Variations in HLA-B cell surface expression, half-life and extracellular antigen receptivity. <i>ELife</i> , 2018, 7, .	6.0	39
22	High-throughput next-generation sequencing to genotype six classical HLA loci from 96 donors in a single MiSeq run. <i>Hla</i> , 2017, 90, 284-291.	0.6	26
23	Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. <i>PLoS Pathogens</i> , 2017, 13, e1006510.	4.7	63
24	Highlights from the HIV Research for Prevention Conference (R4P),: 17-21 October 2016, Chicago, IL, USA. <i>Journal of Virus Eradication</i> , 2017, 3, 92-96.	0.5	1
25	HIV-1 Vpu Mediates HLA-C Downregulation. <i>Cell Host and Microbe</i> , 2016, 19, 686-695.	11.0	127
26	Effect of cytokines on Siglec-1 and HIV-1 entry in monocyte-derived macrophages: the importance of HIV-1 envelope V1V2 region. <i>Journal of Leukocyte Biology</i> , 2016, 99, 1089-1106.	3.3	19
27	HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015, 7, 296ra112.	12.4	47
28	HLA class II diversity in HIV-1 uninfected individuals from the placebo arm of the RV144 Thai vaccine efficacy trial. <i>Tissue Antigens</i> , 2015, 85, 117-126.	1.0	12
29	HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. <i>Nature Medicine</i> , 2015, 21, 1139-1141.	30.7	50
30	High-throughput multiplex HLA genotyping by next-generation sequencing using multi-locus individual tagging. <i>BMC Genomics</i> , 2014, 15, 864.	2.8	67
31	HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial. <i>Immunogenetics</i> , 2014, 66, 299-310.	2.4	14
32	FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. <i>Journal of Clinical Investigation</i> , 2014, 124, 3879-3890.	8.2	99
33	Influence of HLA-C Expression Level on HIV Control. <i>Science</i> , 2013, 340, 87-91.	12.6	352
34	A Novel Variant Marking HLA-DP Expression Levels Predicts Recovery from Hepatitis B Virus Infection. <i>Journal of Virology</i> , 2012, 86, 6979-6985.	3.4	162
35	HLA/KIR Restraint of HIV: Surviving the Fittest. <i>Annual Review of Immunology</i> , 2011, 29, 295-317.	21.8	135
36	Ex vivo functional responses to HLA-G differ between blood and decidual NK cells. <i>Molecular Human Reproduction</i> , 2011, 17, 577-586.	2.8	34

#	ARTICLE	IF	CITATIONS
37	Analysis of Binding of KIR3DS1*014 to HLA Suggests Distinct Evolutionary History of KIR3DS1. Journal of Immunology, 2011, 187, 2162-2171.	0.8	29
38	Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology. Blood, 2010, 115, 4820-4823.	1.4	68
39	HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nature Genetics, 2009, 41, 1290-1294.	21.4	265
40	Novel <i>KIR3DL1</i> Alleles and Their Expression Levels on NK Cells: Convergent Evolution of <i>KIR3DL1</i> Phenotype Variation?. Journal of Immunology, 2008, 180, 6743-6750.	0.8	60
41	Interaction between RANTES Promoter Variant and CCR5 <sup>Δ32</sup> Favors Recovery from Hepatitis B. Journal of Immunology, 2008, 181, 7944-7947.	0.8	22
42	A Case-Control Study on the Association of Human Leukocyte Antigen-A*9 and -B*15 Alleles With Generalized Aggressive Periodontitis in an Indian Population. Journal of Periodontology, 2006, 77, 1954-1963.	3.4	18
43	Association of an Extended Haplotype of HLA Class I Alleles and Their Flanking Microsatellites with Spondyloarthropathies in South Indian Patients. Human Immunology, 2006, 67, 318-323.	2.4	12
44	A crypto-Dravidian origin for the nontribal communities of South India based on human leukocyte antigen class I diversity. Tissue Antigens, 2006, 68, 225-234.	1.0	26
45	HLA-A allele frequency and haplotype distribution in the dravidian tribal communities of south India. Indian Journal of Human Genetics, 2005, 11, 140.	0.7	8
46	HLA-B and HLA-C alleles and haplotypes in the Dravidian tribal populations of southern India. Tissue Antigens, 2004, 64, 58-65.	1.0	16
47	Association of HLA-A*9 and A*10 with Aggressive Periodontitis in South India. International Journal of Human Genetics, 2004, 4, 137-140.	0.1	1
48	Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. Radiotherapy and Oncology, 1994, 33, 113-116.	0.6	80